Brexucabtagene Autoleucel

Collaboration aims to facilitate efficient access to therapies as Kite expands treatment center network CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite , a Gilead Company, to support the distribution of Kite’s U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta ® (axicabtagene ciloleucel) and Tecartus ® (brexucabtagene autoleucel). The collaboration is designed to support efficient access to the cell therapies at the increasing number of authorized treatment centers in the U.S., including health systems and community oncology practices. “Our focus is on ensuring every appropriate patient who needs our CAR T-cell therapies can access and benefit from these treatments,” said Christophe Griolet, U.S. Vice President, General Manager, Kite . “Cencora has a proven track record of supporting complex therapies. As we expand our treatment center network, Cencora’s specialty distribution infrastructure and expertise will support a seamless experience across new and existing sites, reducing provider barriers and enabling us to meet patients where they are.” “Delivering on the promise of CAR T requires a connected ecosystem,” said Mark Kelley, Senior Director, Enterprise Cell and Gene Therapy (CGT) Business Development and Account Management, Cencora . "We share Kite's commitment to expanding patient access and will deliver the services needed to help these therapies reach the patients who need them." "Cell therapies are individualized treatments made from a patient’s own cells, and pose unique challenges to healthcare providers, including health systems and community practices," said Melissa Lattanzi, Vice President of Emerging Therapies, Cencora. " As Kite expands its treatment center network, we will leverage our distribution infrastructure and services to support efficient access and reduce administrative burdens — including order management — across sites of care, advancing Kite's goal to bring therapies closer to patients' homes." Through its CGT service line, Cencora provides developers integrated solutions across the product lifecycle to help them bring products to market, streamline market entry and support efficient access. To learn more about Cencora’s CGT capabilities, visit: About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $300 billion in annual revenue. Contacts Mike Iorfino Mike.Iorfino@cencora.com

Gilead Sciences' stock yo-yoed during after-hours trade Thursday after it revealed that $11.5-billion in anticipated charges related to its M&A spree will likely affect full-year earnings. Instead of an $8.45 to $8.85 per-share profit, as previously projected, the company is now guiding for an adjusted loss of $1.05 to $0.65 a share for 2026. The biopharma made upfront payments of $1.675 billion and $3.15 billion, respectively, to buy Ouro Medicines and Tubulis, while its deal to acquire cell therapy partner Arcellx is valued at about $7.8 billion (see – Vital Signs: The biggest spenders of the first quarter).While the market's early reaction to the news was negative, taking Gilead's shares down as much as 4% after the bell, the drugmaker's first-quarter earnings print also featured several revenue beats and a raise for its full-year sales guidance that seemed to soften the blow. Its share price recovered slightly following a call with investors, ending up about 1% in the red. During that call, Gilead Chief Financial Officer Andrew Dickinson assured investors that they "should still expect very strong financial performance, on the bottom line and the top line.""The business continues to perform really well. You see that in our updated guidance, including the increase in the revenue guidance. You also see the ability to absorb all three of these deals, essentially, and to offset with the revenue outperformance the incremental expenses that we expect this year," he said. "We spent a lot of time planning for this as we were looking at the transaction. So we feel very comfortable about the ability to navigate the incremental expenses."HIV's growth spurtCharges aside, Gilead's first-quarter revenues increased about 4% year-over-year to $6.96 billion, edging ahead of analyst estimates of about $6.91 billion. Its sales were bolstered by its HIV portfolio, which grew 10% to $5 billion for the three-month period. The company's HIV treatment Biktarvy, its twice-yearly pre-exposure prophylaxis (PrEP) injection Yeztugo, and once-daily pill Descovy each beat the Street's expectations. The former raked in $3.36 billion (+7%), slightly ahead of a $3.32-billion forecast, while Descovy sales of $807 million (+38%) blew past predictions of $671 million. Recently launched Yeztugo posted sales of $166 million, an increase of nearly 73% from the previous quarter and beating analysts' $143-million estimate. Its impressive growth prompted Gilead to revise its expectations, and the company is now projecting $1 billion in 2026 sales from the PrEP therapy — an update likely welcomed by investors, as its earlier guidance of $800 million had disappointed. For its HIV portfolio as a whole, Gilead now expects 8% growth for 2026, up from a prior prediction of 6%. Overall, the biopharma raised both ends of its full-year product sales guidance by $400 million. It now expects sales in the range of $30 billion to $30.4 billion, boosted from its previously guided $29.6 billion to $30 billion. Other product sales Outside of HIV, Gilead's liver disease portfolio sales increased 1% to $767 million, thanks mainly to Livdelzi, which generated $133 million for the quarter.Within oncology, Gilead's cell therapy business continued to decline, with sales for Yescarta and Tecartus falling 12% and 4% year-over-year, respectively, to bring in $332 million and $75 million. The drop was driven mainly by competition, the company noted. Sales for its antibody-drug conjugate Trodelvy increased 37% to $402 million for the three-month period.